Open AccessPerformance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis
Author(s) -
Péter Hoffmann,
Cyrill Wehling,
Johannes Krisam,
Jan Pfeiffenberger,
Nina Belling,
Annika Gauss
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i13.1603
Subject(s) - tacrolimus , medicine , ulcerative colitis , colectomy , clinical endpoint , gastroenterology , calcineurin , inflammatory bowel disease , hepatology , refractory (planetary science) , disease , clinical trial , transplantation , physics , astrobiology
Acute severe ulcerative colitis unresponsive to systemic steroid treatment is a life-threatening medical condition requiring hospitalization and often colectomy. Despite the increasing choice of medical therapy options for ulcerative colitis, the condition remains a great challenge in the field of inflammatory bowel diseases (IBD). The performance of the calcineurin inhibitor tacrolimus in this clinical setting is insufficiently elucidated.